R3 Stem Cell today announced its recognition on CIO Bulletin’s “Best Regenerative Medicine & Stem Cell Training Companies 2026” list

“The defining vision was to bring stem cell therapy to the masses, it shouldn’t be just for the 1% who can afford a super expensive treatment, It should be available to most of the population.”

— CEO David Greene, MD, PhD, MBA

SCOTTSDALE, AZ, UNITED STATES, September 1, 2026 /EINPresswire.com/ — R3 Stem Cell, a global leader in regenerative medicine, today announced its recognition on CIO Bulletin’s “Best Regenerative Medicine & Stem Cell Training Companies 2026” list. The honor was announced alongside an extensive cover profile on the company in CIO Bulletin’s September Edition 2026, in which Founder and CEO Dr. David Greene, MD, PhD, MBA, discussed the company’s origins, its clinical and research milestones, and its vision for the future of regenerative care.

R3 Stem Cell operates more than 90 Centers of Excellence across eight countries and has performed over 30,000 stem cell and exosome procedures over the past decade. The company is the only U.S. organization to hold Institutional Review Board (IRB) approval for a Global Observational Safety Database for umbilical cord stem cell therapies, and it offers more than 20 customized treatment protocols with an 85% patient satisfaction rate.

“The defining vision was to bring stem cell therapy to the masses, meaning it shouldn’t be just for the 1% who can afford a super expensive treatment,” said Dr. Greene. “It should be available to a large percentage of the population at a reasonable price point and the highest quality imaginable.”

Founded in 2011 while Dr. Greene was completing his Executive MBA at Arizona State University, R3 Stem Cell has grown into the largest provider of regenerative therapies globally, with a portfolio that includes advanced stem cell and exosome protocols, its proprietary Regenerative Trifecta combination therapy, and hands-on physician training through R3 Medical Training, where attendees train on live patients rather than cadavers or animal tissue. The MSK Ultrasound injection courses receive rave reviews from attendees due to the hands on experience. The company has published more than a dozen peer-reviewed research studies and has vertically integrated its supply chain through GMP tissue processing labs in Scottsdale, Arizona, and Pakistan.

R3’s growth has been supported by partnerships with public figures who have undergone treatment and shared their experiences, including actor Dennis Quaid, Journey Lead Singer Arnel Pineda, boxing world champions Butterbean and Shannon Briggs, WWE Hall of Famer Titus O’Neill, and Super Bowl champion Vernon Davis, alongside thousands of patient success stories documented across R3’s YouTube channel, which has grown to more than 1,500 educational videos.

“I’d like to stay at the forefront of regenerative medicine with clinical therapies, research, and operating stem cell laboratories that will improve the quality of life for patients globally,” Dr. Greene said. “At the same time, my vision is to continue building the business into more countries and become the Marriott of stem cell therapy.”

Looking ahead, R3 is developing Natural Killer (NK) cell immunotherapy in partnership with a university research team, with testing underway to evaluate its effectiveness against multiple cancer cell lines and its potential role in treating autoimmune conditions. R3 Stem Cell offers free consultations globally by calling +1 (844) GET-STEM.

About R3 Stem Cell

R3 Stem Cell is a multinational regenerative medicine provider with more than 90 Centers of Excellence across eight countries. Founded by Dr. David Greene, MD, PhD, MBA, the company delivers personalized stem cell and exosome therapies internationally for patients dealing with chronic pain, injury, autoimmune disease, and other conditions, and provides CME-accredited physician training through R3 Medical Training. R3 has been named Stem Cell Global Company of the Year for five consecutive years by Corporate Vision, IE100, and other industry publications.

Media Contact:
CEO David Greene, MD, PhD, MBA
+1 (844) GET-STEM
info@r3stemcell.com

David Greene, MD, PhD, MBA
R3 Stem Cell International
+1 (888) 988-0515
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
TikTok

Legal Disclaimer:

EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Media gallery

About The Author
Written By: EIN Presswire